disease-modifying therapies

R&D

The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.

News

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.